Lyora Therapeutics, Inc., a biotech startup aiming to harness the power of genetic medicines for vision, has closed a $2.5M pre-seed funding round. The capital infusion marks an early vote of confidence in the company's mission to develop therapies for the durable preservation and restoration of sight.
The company's focus on genetic medicines positions it in a rapidly evolving field, seeking to address the root causes of vision impairment. This initial funding will support Lyora's foundational research and development efforts as it works towards its goal of bringing innovative solutions to patients.
.png&w=3840&q=75)
